Skip to content


  • Poster presentation
  • Open Access

Endovascular treatment of superior vena cava syndrome. A systematic review

  • 1Email author,
  • 2,
  • 1,
  • 3 and
  • 1
Journal of Cardiothoracic Surgery20138 (Suppl 1) :P133

  • Published:


  • Lung Cancer
  • Stent Placement
  • Endovascular Treatment
  • Clinical Success
  • Technical Success


The purpose of this study is the systematic review of literature on endovascular treatment (EVT) of patients with superior vena cava syndrome (SVCS).


A systematic keyword-based research in online libraries and databases from 1980 until today was performed. We found 43 related publications. Specifically, 13 retrospective, clinical, observational studies with large patient series (>10), 2 clinical studies reviews, 3 guidelines and 25 case reports.


The most frequent cause of superior vena cava syndrome was lung cancer. Endovascular treatment of the syndrome was accomplished via stent placement with or without angioplasty. The technical success of the method was very high (96.75%) and the corresponding clinical success was similarly high (94%). Primary patency was 87.4% on average, while secondary patency was 93.5%. The rate of syndrome recurrence after stent placement varied from 13-20% and was not related to the technical method, but it did depend on primary disease progression. The complications of the method are minimal and in very experienced centers virtually zero.


Endovascular treatment of superior vena cava syndrome with stent placement is a safe treatment option with very high efficiency and immediate clinical benefit for the patients. Therefore, we recommend endovascular treatment as the first line therapeutic approach of the syndrome.

Authors’ Affiliations

Thoracic Surgery Department, Theagenio Cancer Hospital, Thessaloniki, Greece
Radiotherapy Oncology Department, Theagenio Cancer Hospital, Thessaloniki, Greece
Vascural Surgery Department, Konstantopoulio General Hospital, Athens, Greece


© Kleontas et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.